Target intelligence / Profile preview

KRAS G12V-derived antigenic determinant (KRAS G12V neoantigen)

Target
KRAS G12V neoantigen
Molecular classification
Other
01

Overview

KRAS G12V-derived antigenic determinant refers to the tumor-specific neoantigen or peptide epitope generated by the somatic G12V mutation (glycine-to-valine substitution at codon 12) in the KRAS oncogene. KRAS is a small GTPase that plays a critical role in regulating cell growth, survival, and differentiation, and its G12V mutation is highly prevalent in aggressive malignancies such as pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Because this mutation is unique to cancer cells and absent in healthy tissues, the resulting mutated peptide is processed and presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules (most notably HLA-A*11:01 and HLA-A*03:01), serving as an ideal, highly specific target for cancer immunotherapy. Therapeutic strategies targeting the KRAS G12V-derived antigenic determinant include adoptive cell therapies like T-cell receptor-engineered T-cell (TCR-T) therapy (e.g., NW-301V, RE001), T-cell receptor-guided T-cell engagers (TCR-TCEs) or bispecific antibodies (e.g., MDG3010), and therapeutic cancer vaccines (e.g., ELI-002, mKRAS-VAX, and mRNA-based vaccines). These therapies aim to direct the patient's immune system to selectively recognize and destroy KRAS G12V-expressing tumor cells. Clinical development of these agents relies heavily on patient selection using biomarkers such as the presence of the KRAS G12V mutation and specific HLA genotypes. While these immunotherapies offer a promising, highly precise approach to treating difficult solid tumors, challenges include potential tumor immune escape via HLA downregulation, T-cell exhaustion, and the risk of systemic inflammatory responses like cytokine release syndrome.

Other names
KRAS G12V neoantigenKRAS G12V mutant peptideKRAS G12V epitopeKRAS G12V mutant antigenKRAS G12V-derived neoantigenKRAS G12V-derived epitopeKRAS G12V-derived peptideKRAS G12V-derived tumor-specific antigen
02

Mechanism of action

Stimulation of host T-cell responses or redirection of engineered T-cells/T-cell engagers to specifically recognize and eliminate tumor cells presenting the KRAS G12V mutant peptide in complex with human leukocyte antigen (HLA) molecules.

03

Biological functions

Immune responseOther
04

Disease associations

Cancer
05

Safety considerations

Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)On-target, off-tumor toxicity due to potential cross-reactivityTumor immune escape via HLA downregulation or antigen lossT-cell exhaustionInjection site reactionsFlu-like symptomsFatigueChills
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

KRAS G12V mutationHLA-A*11:01 genotypeHLA-A*03:01 genotypeHLA-DPB1*03:01 genotypeHLA-DPB1*14:01 genotypeCirculating tumor DNA (ctDNA)CA19-9Interferon-gamma (IFN-γ) producing T cells

Beyond the preview

Go deeper on KRAS G12V-derived antigenic determinant (KRAS G12V neoantigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRAS G12V-derived antigenic determinant (KRAS G12V neoantigen).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call